Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Core Insights - Propanc Biopharma, Inc. is focusing on developing PRP, a novel therapeutic approach for treating and preventing metastatic cancer, particularly pancreatic cancer, which has a low five-year survival rate of 13% [1][2] Company Overview - Propanc Biopharma, Inc. is a biopharmaceutical company dedicated to creating treatments for chronic diseases, including recurrent and metastatic cancer [1][7] - The lead product candidate, PRP, aims to target cancer stem cells and prevent cancer recurrence and metastasis through proenzyme activation [7] Product Details - PRP is an investigational proenzyme therapy consisting of trypsinogen and chymotrypsinogen in a 1:6 ratio, delivered intravenously [3] - Unlike traditional cytotoxic drugs, PRP specifically targets cancer stem cells, suppresses epithelial-mesenchymal transition (EMT), disrupts the tumor microenvironment, curbs angiogenesis, and enhances chemosensitivity [3] Preclinical Data - Preclinical studies show over 85% tumor growth inhibition in pancreatic cancer models, with reduced fibrosis and resistance markers, and a favorable safety profile with no major side effects reported in limited human use [4] - A small compassionate study indicated that PRP extended survival from approximately 5.6 months to 9 months in advanced cases [4] Market Potential - The global pancreatic cancer treatment market is valued at approximately $4.42 billion in 2026 and is projected to grow to $14.43 billion by 2034, with a compound annual growth rate (CAGR) of around 16% [5] - Propanc is preparing for a Phase 1b First-In-Human trial in 2026, involving 30-40 advanced solid tumor patients, supported by a $100 million funding facility and FDA Orphan Drug status for pancreatic cancer [5] Competitive Advantages - PRP has the potential to enhance the effectiveness of standard treatments while reducing toxicity, making it a promising alternative to existing therapies [6][9] - The therapy may also sensitize resistant tumors to chemotherapy and remodel the tumor microenvironment to improve immunotherapy outcomes [9]